All In Biotech

Drug Trial Radar · NCT04315467

Intraoperative Imaging of Pulmonary Nodules by SGM-101

Intraoperative Molecular Imaging Of Pulmonary Nodules By SGM-101, A Fluorochrome-Labeled Anti-Carcino-Embryonic Antigen (CEA) Monoclonal Antibody

Last checked: Nov 19, 2026Latest source record: Jun 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Jul 8, 2020

Primary completion

Feb 10, 2022

Study completion Feb 10, 2022

Sponsor

Lead sponsor
Sunil SinghalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to assess the sensitivity and specificity of SGM-101 in detecting non-small cell lung carcinomas during surgery when excited by an near-infrared light source utilizing intraoperative imaging.

Conditions

  • Lung Cancer
  • Lung Nodule
  • Non Small Cell Lung Cancer

Interventions

  • SGM-101Drug

    A one-time infusion of SGM-101

  • Near infrared camera imaging systemDevice

    Near infrared camera imaging system

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity measure of SGM-101 uptake and expression in identifying non-small cell lung cancerTime frame: Up to 10 days post surgery (completion of pathology report)
  2. Specificity measure of SGM-101 uptake and expression in identifying non-small cell lung cancerTime frame: Up to 10 days post surgery (completion of pathology report)
  3. Number of Adverse Events (AEs) and Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 4 weeks post surgery (completion of post-operative follow-up visit)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.